Read More Pharma Industry News Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA. bySoujanya RaviNovember 8, 2025